Edgewise Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $274.4M | $15.6M |
| FY2022 | — | $346.7M | $22.0M |
| FY2023 | — | $318.8M | $86.1M |
| FY2024 | — | $459.2M | $41.7M |
| FY2025 | — | $522.3M | $61.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $274.4M | $15.6M |
| FY2022 | — | $346.7M | $22.0M |
| FY2023 | — | $318.8M | $86.1M |
| FY2024 | — | $459.2M | $41.7M |
| FY2025 | — | $522.3M | $61.1M |